Ruxolitinib

Common brands: Jakafi, Opzelura, Jakafi Xr, Aspirin 325, Aspirin 81

Top reporter: Incyte Corporation

Janus Kinase Inhibitor [EPC]Kinase Inhibitor [EPC]Corticosteroid [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Platelet Aggregation Inhibitor [EPC]
69,262
Total Reports
39,069
Serious Reports
9,621
Death Reports
30
Reported Reactions
Death Report Ratio: High (13.89%)

Patient Demographics

Male
10,631
Female
10,002

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Ruxolitinib.

# Reaction Reports % of Total
1 OFF LABEL USE 13,948
17.6%
2 DEATH 6,288
7.9%
3 FATIGUE 5,973
7.5%
4 ANAEMIA 3,032
3.8%
5 HAEMOGLOBIN DECREASED 2,933
3.7%
6 PLATELET COUNT DECREASED 2,668
3.4%
7 DIARRHOEA 2,624
3.3%
8 PRODUCT DOSE OMISSION ISSUE 2,491
3.1%
9 ASTHENIA 2,485
3.1%
10 DIZZINESS 2,458
3.1%
11 HEADACHE 2,371
3.0%
12 PRODUCT AVAILABILITY ISSUE 2,276
2.9%
13 PNEUMONIA 2,113
2.7%
14 NAUSEA 2,086
2.6%
15 DRUG INEFFECTIVE 2,079
2.6%
16 WEIGHT INCREASED 1,951
2.5%
17 DYSPNOEA 1,944
2.5%
18 PAIN 1,807
2.3%
19 PRURITUS 1,728
2.2%
20 SPLENOMEGALY 1,722
2.2%
21 MALAISE 1,573
2.0%
22 PYREXIA 1,526
1.9%
23 PLATELET COUNT INCREASED 1,509
1.9%
24 FALL 1,488
1.9%
25 CONTUSION 1,479
1.9%
26 PRODUCT DOSE OMISSION 1,373
1.7%
27 THROMBOCYTOPENIA 1,337
1.7%
28 WHITE BLOOD CELL COUNT INCREASED 1,321
1.7%
29 ARTHRALGIA 1,297
1.6%
30 DRUG DOSE OMISSION 1,250
1.6%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.